首页 > 最新文献

Current Opinion in Ophthalmology最新文献

英文 中文
Retinal arterial and vein occlusion: is surgery ever indicated? 视网膜动静脉闭塞:是否需要手术?
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-28 DOI: 10.1097/ICU.0000000000001045
Kazuaki Kadonosono, Maiko Inoue, Yasuo Yanagi

Purpose of review: To highlight the recent progression in surgical treatments for central retinal vein occlusion (CRVO) and central retinal artery occlusion (CRAO).

Recent findings: Anti-VEGF treatment, accepted as a primary treatment for CRVO, is unable to effectively treat all types of the diseases. Regarding CRAO, there are not any accepted therapies available. There have however been recent innovations in surgery, such as utilizing robotics-assisted tools in cannulation procedures for central retinal artery occlusion, or micro-cystotomy for refractory macular edema resulting from ischemic CRVO.

Summary: Refractory macular edema due to CRVO can be treated with aspiration of the fluid found inside the large cysts often seen in edema. The success rate of micro-cystotomy has been reported at 78% in eyes with refractory macular edema. Recent studies have shown that cannulation with tissue plasminogen activator (tPA) is effective for eyes with CRAO due to thrombus.Recent cannulation or micro-cystotomy procedures can be enhanced with the use of robotic tools which allow us to perform this difficult procedure more easily. Newly developed technology, and consequent developments in surgical procedures, will allow us to deal with unmet needs for retinal vessel occlusive diseases.

综述目的:重点介绍视网膜中央静脉闭塞(CRVO)和视网膜中央动脉闭塞(CRAO)手术治疗的最新进展:最新发现:抗血管内皮生长因子治疗被认为是治疗 CRVO 的主要方法,但无法有效治疗所有类型的疾病。至于 CRAO,目前还没有任何公认的疗法。不过,最近在手术方面有所创新,例如利用机器人辅助工具进行视网膜中央动脉闭塞的插管手术,或对缺血性 CRVO 引起的难治性黄斑水肿进行微囊切开术:由 CRVO 引起的难治性黄斑水肿可通过抽吸水肿中常见的大囊肿内的液体来治疗。据报道,在患有难治性黄斑水肿的眼睛中,显微囊肿切开术的成功率为78%。最近的研究表明,使用组织纤溶酶原激活剂(tPA)插管对因血栓导致的 CRAO 眼球有效。最近的插管或微囊切开术可通过使用机器人工具得到改进,使我们能更轻松地完成这一高难度手术。新开发的技术以及随之而来的手术程序的发展,将使我们能够应对视网膜血管闭塞疾病方面尚未得到满足的需求。
{"title":"Retinal arterial and vein occlusion: is surgery ever indicated?","authors":"Kazuaki Kadonosono, Maiko Inoue, Yasuo Yanagi","doi":"10.1097/ICU.0000000000001045","DOIUrl":"10.1097/ICU.0000000000001045","url":null,"abstract":"<p><strong>Purpose of review: </strong>To highlight the recent progression in surgical treatments for central retinal vein occlusion (CRVO) and central retinal artery occlusion (CRAO).</p><p><strong>Recent findings: </strong>Anti-VEGF treatment, accepted as a primary treatment for CRVO, is unable to effectively treat all types of the diseases. Regarding CRAO, there are not any accepted therapies available. There have however been recent innovations in surgery, such as utilizing robotics-assisted tools in cannulation procedures for central retinal artery occlusion, or micro-cystotomy for refractory macular edema resulting from ischemic CRVO.</p><p><strong>Summary: </strong>Refractory macular edema due to CRVO can be treated with aspiration of the fluid found inside the large cysts often seen in edema. The success rate of micro-cystotomy has been reported at 78% in eyes with refractory macular edema. Recent studies have shown that cannulation with tissue plasminogen activator (tPA) is effective for eyes with CRAO due to thrombus.Recent cannulation or micro-cystotomy procedures can be enhanced with the use of robotic tools which allow us to perform this difficult procedure more easily. Newly developed technology, and consequent developments in surgical procedures, will allow us to deal with unmet needs for retinal vessel occlusive diseases.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"210-216"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on corneal crosslinking for keratoconus and corneal ectasia. 角膜交联治疗角膜炎和角膜异位症的最新进展。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 DOI: 10.1097/icu.0000000000001056
Steven A Greenstein, Peter S Hersh
To review corneal crosslinking for keratoconus and corneal ectasia, and recent developments in the field. This study will review the mechanism of crosslinking, clinical approaches, current results, and potential future innovations.
综述角膜交联治疗角膜炎和角膜异位症的方法以及该领域的最新进展。本研究将回顾交联的机制、临床方法、当前成果以及未来可能的创新。
{"title":"Update on corneal crosslinking for keratoconus and corneal ectasia.","authors":"Steven A Greenstein, Peter S Hersh","doi":"10.1097/icu.0000000000001056","DOIUrl":"https://doi.org/10.1097/icu.0000000000001056","url":null,"abstract":"To review corneal crosslinking for keratoconus and corneal ectasia, and recent developments in the field. This study will review the mechanism of crosslinking, clinical approaches, current results, and potential future innovations.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"66 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140826735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ChatGPT enters the room: what it means for patient counseling, physician education, academics, and disease management. ChatGPT 进入病房:它对病人咨询、医生教育、学术和疾病管理的意义。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-07 DOI: 10.1097/ICU.0000000000001036
Bita Momenaei, Hana A Mansour, Ajay E Kuriyan, David Xu, Jayanth Sridhar, Daniel S W Ting, Yoshihiro Yonekawa

Purpose of review: This review seeks to provide a summary of the most recent research findings regarding the utilization of ChatGPT, an artificial intelligence (AI)-powered chatbot, in the field of ophthalmology in addition to exploring the limitations and ethical considerations associated with its application.

Recent findings: ChatGPT has gained widespread recognition and demonstrated potential in enhancing patient and physician education, boosting research productivity, and streamlining administrative tasks. In various studies examining its utility in ophthalmology, ChatGPT has exhibited fair to good accuracy, with its most recent iteration showcasing superior performance in providing ophthalmic recommendations across various ophthalmic disorders such as corneal diseases, orbital disorders, vitreoretinal diseases, uveitis, neuro-ophthalmology, and glaucoma. This proves beneficial for patients in accessing information and aids physicians in triaging as well as formulating differential diagnoses. Despite such benefits, ChatGPT has limitations that require acknowledgment including the potential risk of offering inaccurate or harmful information, dependence on outdated data, the necessity for a high level of education for data comprehension, and concerns regarding patient privacy and ethical considerations within the research domain.

Summary: ChatGPT is a promising new tool that could contribute to ophthalmic healthcare education and research, potentially reducing work burdens. However, its current limitations necessitate a complementary role with human expert oversight.

综述目的本综述旨在总结人工智能(AI)驱动的聊天机器人 ChatGPT 在眼科领域应用的最新研究成果,并探讨与其应用相关的局限性和伦理问题:ChatGPT 已获得广泛认可,并在加强患者和医生教育、提高研究效率和简化行政工作方面展现出巨大潜力。在对 ChatGPT 在眼科领域的实用性进行的多项研究中,ChatGPT 都表现出了相当到良好的准确性,其最新迭代版本在为角膜疾病、眼眶疾病、玻璃体视网膜疾病、葡萄膜炎、神经眼科和青光眼等各种眼科疾病提供眼科建议方面表现出了卓越的性能。事实证明,这有利于患者获取信息,并帮助医生进行分流和制定鉴别诊断。小结:ChatGPT 是一种很有前途的新工具,可为眼科医疗保健教育和研究做出贡献,并有可能减轻工作负担。然而,由于其目前的局限性,有必要在人类专家的监督下发挥辅助作用。
{"title":"ChatGPT enters the room: what it means for patient counseling, physician education, academics, and disease management.","authors":"Bita Momenaei, Hana A Mansour, Ajay E Kuriyan, David Xu, Jayanth Sridhar, Daniel S W Ting, Yoshihiro Yonekawa","doi":"10.1097/ICU.0000000000001036","DOIUrl":"10.1097/ICU.0000000000001036","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review seeks to provide a summary of the most recent research findings regarding the utilization of ChatGPT, an artificial intelligence (AI)-powered chatbot, in the field of ophthalmology in addition to exploring the limitations and ethical considerations associated with its application.</p><p><strong>Recent findings: </strong>ChatGPT has gained widespread recognition and demonstrated potential in enhancing patient and physician education, boosting research productivity, and streamlining administrative tasks. In various studies examining its utility in ophthalmology, ChatGPT has exhibited fair to good accuracy, with its most recent iteration showcasing superior performance in providing ophthalmic recommendations across various ophthalmic disorders such as corneal diseases, orbital disorders, vitreoretinal diseases, uveitis, neuro-ophthalmology, and glaucoma. This proves beneficial for patients in accessing information and aids physicians in triaging as well as formulating differential diagnoses. Despite such benefits, ChatGPT has limitations that require acknowledgment including the potential risk of offering inaccurate or harmful information, dependence on outdated data, the necessity for a high level of education for data comprehension, and concerns regarding patient privacy and ethical considerations within the research domain.</p><p><strong>Summary: </strong>ChatGPT is a promising new tool that could contribute to ophthalmic healthcare education and research, potentially reducing work burdens. However, its current limitations necessitate a complementary role with human expert oversight.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"205-209"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell therapy for retinal disease. 视网膜疾病的细胞疗法。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-01-24 DOI: 10.1097/ICU.0000000000001034
Goutham R Yalla, Ajay E Kuriyan

Purpose of review: This review presents an update on completed stem cell therapy trials aimed at retinal diseases.

Recent findings: In recent years, several clinical trials have been conducted examining the safety and role of cell therapy in diseases, including age-related macular degeneration, Stargardt's macular dystrophy, and retinitis pigmentosa. Studies have utilized a variety of cell lines, modes of delivery, and immunosuppressive regimens. The prevalence of fraudulent cell therapy clinics poses threats to patients.

Summary: Clinical trials have begun to characterize the safety of cell therapy in retinal disease. While studies have described the potential benefits of cell therapy, larger studies powered to evaluate this efficacy are required to continue progressing toward preventing retinal disease. Nonapproved cell therapy clinics require regulation and patient education to avoid patient complications.

综述目的:本综述介绍了针对视网膜疾病的干细胞疗法试验的最新进展:近年来,已进行了多项临床试验,研究细胞疗法在老年性黄斑变性、Stargardt黄斑营养不良症和视网膜色素变性等疾病中的安全性和作用。研究采用了多种细胞系、给药方式和免疫抑制方案。摘要:临床试验已开始描述细胞疗法治疗视网膜疾病的安全性。虽然研究已描述了细胞疗法的潜在益处,但还需要更大规模的研究来评估这种疗效,以继续推进视网膜疾病的预防工作。未经批准的细胞疗法诊所需要监管和患者教育,以避免患者出现并发症。
{"title":"Cell therapy for retinal disease.","authors":"Goutham R Yalla, Ajay E Kuriyan","doi":"10.1097/ICU.0000000000001034","DOIUrl":"10.1097/ICU.0000000000001034","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review presents an update on completed stem cell therapy trials aimed at retinal diseases.</p><p><strong>Recent findings: </strong>In recent years, several clinical trials have been conducted examining the safety and role of cell therapy in diseases, including age-related macular degeneration, Stargardt's macular dystrophy, and retinitis pigmentosa. Studies have utilized a variety of cell lines, modes of delivery, and immunosuppressive regimens. The prevalence of fraudulent cell therapy clinics poses threats to patients.</p><p><strong>Summary: </strong>Clinical trials have begun to characterize the safety of cell therapy in retinal disease. While studies have described the potential benefits of cell therapy, larger studies powered to evaluate this efficacy are required to continue progressing toward preventing retinal disease. Nonapproved cell therapy clinics require regulation and patient education to avoid patient complications.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"178-184"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of artificial intelligence-enabled robots and chatbots in ophthalmology: recent advances and future trends. 人工智能机器人和聊天机器人在眼科中的应用:最新进展和未来趋势。
IF 3 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1097/ICU.0000000000001035
Yeganeh Madadi, Mohammad Delsoz, Albert S Khouri, Michael Boland, Andrzej Grzybowski, Siamak Yousefi

Purpose of review: Recent advances in artificial intelligence (AI), robotics, and chatbots have brought these technologies to the forefront of medicine, particularly ophthalmology. These technologies have been applied in diagnosis, prognosis, surgical operations, and patient-specific care in ophthalmology. It is thus both timely and pertinent to assess the existing landscape, recent advances, and trajectory of trends of AI, AI-enabled robots, and chatbots in ophthalmology.

Recent findings: Some recent developments have integrated AI enabled robotics with diagnosis, and surgical procedures in ophthalmology. More recently, large language models (LLMs) like ChatGPT have shown promise in augmenting research capabilities and diagnosing ophthalmic diseases. These developments may portend a new era of doctor-patient-machine collaboration.

Summary: Ophthalmology is undergoing a revolutionary change in research, clinical practice, and surgical interventions. Ophthalmic AI-enabled robotics and chatbot technologies based on LLMs are converging to create a new era of digital ophthalmology. Collectively, these developments portend a future in which conventional ophthalmic knowledge will be seamlessly integrated with AI to improve the patient experience and enhance therapeutic outcomes.

综述目的:人工智能(AI)、机器人技术和聊天机器人的最新进展将这些技术带到了医学,尤其是眼科的前沿。这些技术已被应用于眼科的诊断、预后、手术操作和特定患者护理。因此,评估人工智能、人工智能机器人和聊天机器人在眼科领域的现有格局、最新进展和发展趋势既及时又贴切:最近的一些发展将人工智能机器人与眼科诊断和手术程序结合在一起。最近,像 ChatGPT 这样的大型语言模型(LLMs)在增强研究能力和诊断眼科疾病方面显示出了前景。摘要:眼科在研究、临床实践和手术干预方面正经历着一场革命性的变革。基于 LLM 的眼科人工智能机器人和聊天机器人技术正在汇聚在一起,开创数字眼科的新时代。这些发展共同预示着未来传统眼科知识将与人工智能无缝结合,从而改善患者体验,提高治疗效果。
{"title":"Applications of artificial intelligence-enabled robots and chatbots in ophthalmology: recent advances and future trends.","authors":"Yeganeh Madadi, Mohammad Delsoz, Albert S Khouri, Michael Boland, Andrzej Grzybowski, Siamak Yousefi","doi":"10.1097/ICU.0000000000001035","DOIUrl":"10.1097/ICU.0000000000001035","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent advances in artificial intelligence (AI), robotics, and chatbots have brought these technologies to the forefront of medicine, particularly ophthalmology. These technologies have been applied in diagnosis, prognosis, surgical operations, and patient-specific care in ophthalmology. It is thus both timely and pertinent to assess the existing landscape, recent advances, and trajectory of trends of AI, AI-enabled robots, and chatbots in ophthalmology.</p><p><strong>Recent findings: </strong>Some recent developments have integrated AI enabled robotics with diagnosis, and surgical procedures in ophthalmology. More recently, large language models (LLMs) like ChatGPT have shown promise in augmenting research capabilities and diagnosing ophthalmic diseases. These developments may portend a new era of doctor-patient-machine collaboration.</p><p><strong>Summary: </strong>Ophthalmology is undergoing a revolutionary change in research, clinical practice, and surgical interventions. Ophthalmic AI-enabled robotics and chatbot technologies based on LLMs are converging to create a new era of digital ophthalmology. Collectively, these developments portend a future in which conventional ophthalmic knowledge will be seamlessly integrated with AI to improve the patient experience and enhance therapeutic outcomes.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"238-243"},"PeriodicalIF":3.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cranial nerve involvement, visual complications and headache syndromes in Lyme disease. 莱姆病的颅神经受累、视觉并发症和头痛综合征。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-08 DOI: 10.1097/ICU.0000000000001031
Caleb R S McEntire, Bart K Chwalisz

Purpose of review: To provide a summary of the visual manifestations and cranial neuropathies seen in Lyme disease.

Recent findings: Lyme facial palsy remains the most common manifestation of Lyme neuroborreliosis. Recent investigations show likely evidence of vagal involvement in Lyme disease.

Summary: The literature on Lyme neuroborreliosis continues to evolve. Lyme disease can affect nearly any cranial nerve in addition to causing various headache syndromes. The most common manifestation is Lyme disease facial palsy, occurring in up to 5-10% of patients with documented Lyme disease. Headache syndromes are common in the context of facial palsy but can occur in isolation, and more specific headache syndromes including trigeminal and geniculate neuralgias can occur rarely. Signs and symptoms indicative of vestibulocochlear nerve involvement are relatively common, although it could be that these represent other vestibular involvement rather than a specific cranial neuropathy. Optic neuritis is a controversial entity within Lyme disease and is likely overdiagnosed, but convincing cases do exist. Physicians who see any cranial neuropathy, including optic neuritis, in an endemic area can consider Lyme disease as a possible cause.

综述的目的:概述莱姆病的视觉表现和颅神经病变:莱姆面瘫仍然是莱姆神经源性疾病最常见的表现。小结:有关莱姆病神经源性莱姆病的文献仍在不断发展。莱姆病除可引起各种头痛综合征外,还可影响几乎所有的颅神经。最常见的表现是莱姆病面瘫,在有记录的莱姆病患者中,面瘫发生率高达 5-10%。头痛综合征常见于面瘫,但也可单独发生,包括三叉神经痛和膝状神经痛在内的更特殊的头痛综合征也很少发生。显示前庭神经受累的体征和症状相对常见,但这些症状可能代表其他前庭神经受累,而非特定的颅神经病变。视神经炎是莱姆病中一个有争议的实体,很可能被过度诊断,但确实存在令人信服的病例。如果医生在莱姆病流行地区发现任何颅神经病变,包括视神经炎,都可以考虑将莱姆病作为可能的病因。
{"title":"Cranial nerve involvement, visual complications and headache syndromes in Lyme disease.","authors":"Caleb R S McEntire, Bart K Chwalisz","doi":"10.1097/ICU.0000000000001031","DOIUrl":"10.1097/ICU.0000000000001031","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide a summary of the visual manifestations and cranial neuropathies seen in Lyme disease.</p><p><strong>Recent findings: </strong>Lyme facial palsy remains the most common manifestation of Lyme neuroborreliosis. Recent investigations show likely evidence of vagal involvement in Lyme disease.</p><p><strong>Summary: </strong>The literature on Lyme neuroborreliosis continues to evolve. Lyme disease can affect nearly any cranial nerve in addition to causing various headache syndromes. The most common manifestation is Lyme disease facial palsy, occurring in up to 5-10% of patients with documented Lyme disease. Headache syndromes are common in the context of facial palsy but can occur in isolation, and more specific headache syndromes including trigeminal and geniculate neuralgias can occur rarely. Signs and symptoms indicative of vestibulocochlear nerve involvement are relatively common, although it could be that these represent other vestibular involvement rather than a specific cranial neuropathy. Optic neuritis is a controversial entity within Lyme disease and is likely overdiagnosed, but convincing cases do exist. Physicians who see any cranial neuropathy, including optic neuritis, in an endemic area can consider Lyme disease as a possible cause.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"35 3","pages":"265-271"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy. 镰状细胞病的全身用药和镰状细胞视网膜病变的潜在应用。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-08 DOI: 10.1097/ICU.0000000000001041
Anupam K Garg, Adrienne W Scott

Purpose of review: To review the literature evaluating systemic medications for treatment of sickle cell disease (SCD) and their applications for sickle cell retinopathy.

Recent findings: Prior studies have demonstrated the efficacy of traditional systemic therapies in reducing the risk of development of sickle cell retinopathy. Since 2017, several new and promising disease-modifying therapies for sickle cell disease have been approved for clinical use, including the first genetic therapies such as exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel). These treatments have shown promising results for systemic management but are not widely utilized due to limited access and high cost. The efficacy of these therapies for the prevention of sickle cell retinopathy remains unknown and opens the door to new avenues for research. Furthermore, the role of systemic therapy for the management of hemoglobin SC (HbSC) disease, which has milder systemic effects but higher likelihood of causing retinopathy, remains poorly understood.

Summary: Hydroxyurea has been a mainstay of systemic management of SCD with prior work suggesting its ability to reduce the likelihood of developing retinopathy. There are several new and potentially curative systemic therapies for SCD, though their role in retinopathy prevention and management has not been studied extensively. Future studies are necessary to understand the implications of these emerging therapies for sickle cell retinopathy.

综述目的:回顾评估治疗镰状细胞病(SCD)的全身用药及其在镰状细胞视网膜病变中应用的文献:先前的研究已证明,传统的全身疗法在降低镰状细胞视网膜病变的发病风险方面具有疗效。自2017年以来,几种新的、有前景的镰状细胞病疾病改变疗法已被批准用于临床,其中包括首批基因疗法,如exagamglogene autotemcel(exa-cel)和lovotibeglogene autotemcel(lovo-cel)。这些疗法在系统管理方面显示出良好的效果,但由于获取途径有限和费用高昂,并未得到广泛应用。这些疗法在预防镰状细胞视网膜病变方面的疗效仍是未知数,这为研究开辟了新的途径。摘要:羟基脲一直是 SCD 全身治疗的主要药物,之前的研究表明羟基脲能够降低发生视网膜病变的可能性。目前有几种新的可能治疗 SCD 的全身疗法,但它们在视网膜病变预防和管理中的作用尚未得到广泛研究。未来有必要开展研究,以了解这些新兴疗法对镰状细胞视网膜病变的影响。
{"title":"Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy.","authors":"Anupam K Garg, Adrienne W Scott","doi":"10.1097/ICU.0000000000001041","DOIUrl":"10.1097/ICU.0000000000001041","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the literature evaluating systemic medications for treatment of sickle cell disease (SCD) and their applications for sickle cell retinopathy.</p><p><strong>Recent findings: </strong>Prior studies have demonstrated the efficacy of traditional systemic therapies in reducing the risk of development of sickle cell retinopathy. Since 2017, several new and promising disease-modifying therapies for sickle cell disease have been approved for clinical use, including the first genetic therapies such as exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel). These treatments have shown promising results for systemic management but are not widely utilized due to limited access and high cost. The efficacy of these therapies for the prevention of sickle cell retinopathy remains unknown and opens the door to new avenues for research. Furthermore, the role of systemic therapy for the management of hemoglobin SC (HbSC) disease, which has milder systemic effects but higher likelihood of causing retinopathy, remains poorly understood.</p><p><strong>Summary: </strong>Hydroxyurea has been a mainstay of systemic management of SCD with prior work suggesting its ability to reduce the likelihood of developing retinopathy. There are several new and potentially curative systemic therapies for SCD, though their role in retinopathy prevention and management has not been studied extensively. Future studies are necessary to understand the implications of these emerging therapies for sickle cell retinopathy.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"185-191"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ever-evolving landscape of medical and surgical management of retinal disease. 视网膜疾病的内外科治疗不断发展。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-26 DOI: 10.1097/ICU.0000000000001042
Ajay E Kuriyan, Jayanth Sridhar
{"title":"The ever-evolving landscape of medical and surgical management of retinal disease.","authors":"Ajay E Kuriyan, Jayanth Sridhar","doi":"10.1097/ICU.0000000000001042","DOIUrl":"10.1097/ICU.0000000000001042","url":null,"abstract":"","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"35 3","pages":"163-164"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Femtosecond laser-assisted in situ keratomileusis versus small-incision lenticule extraction: current approach based on evidence. 飞秒激光辅助原位角膜磨镶术与小切口皮瓣摘除术:基于证据的现行方法。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 DOI: 10.1097/icu.0000000000001060
Zhen Ling Teo, Marcus Ang
Laser keratorefractive surgery achieves excellent visual outcomes for refractive error correction. With femtosecond laser, small incision lenticule extraction (SMILE) is an increasingly viable alternative to laser-assisted in situ keratomileusis (LASIK). Comparative studies demonstrate similar efficacy and predictability between SMILE and LASIK, making it difficult for clinicians to choose which to use. This review thus compares femtosecond-LASIK (FS-LASK) and SMILE in various scenarios, to assist clinicians in deciding which refractive surgery procedure to recommend.
激光角膜屈光手术在矫正屈光不正方面取得了极佳的视觉效果。利用飞秒激光,小切口皮瓣摘除术(SMILE)越来越成为激光辅助原位角膜磨镶术(LASIK)的可行替代方案。比较研究表明,SMILE 和 LASIK 具有相似的疗效和可预测性,因此临床医生很难选择使用哪种方法。因此,本综述比较了飞秒激光角膜屈光手术(FS-LASK)和飞秒激光原位角膜磨镶术(SMILE)在不同情况下的效果,以帮助临床医生决定推荐哪种屈光手术方法。
{"title":"Femtosecond laser-assisted in situ keratomileusis versus small-incision lenticule extraction: current approach based on evidence.","authors":"Zhen Ling Teo, Marcus Ang","doi":"10.1097/icu.0000000000001060","DOIUrl":"https://doi.org/10.1097/icu.0000000000001060","url":null,"abstract":"Laser keratorefractive surgery achieves excellent visual outcomes for refractive error correction. With femtosecond laser, small incision lenticule extraction (SMILE) is an increasingly viable alternative to laser-assisted in situ keratomileusis (LASIK). Comparative studies demonstrate similar efficacy and predictability between SMILE and LASIK, making it difficult for clinicians to choose which to use. This review thus compares femtosecond-LASIK (FS-LASK) and SMILE in various scenarios, to assist clinicians in deciding which refractive surgery procedure to recommend.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"58 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140826947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New forays into measurement of ocular biomechanics. 测量眼部生物力学的新探索。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-13 DOI: 10.1097/ICU.0000000000001032
Emma Hammelef, Christopher J Rapuano, Dominick A Benedetto, Zeba A Syed, Jonathan S Myers, M Reza Razeghinejad, Fred H Silver, Jose S Pulido

Purpose of review: The field of corneal biomechanics has rapidly progressed in recent years, reflecting technological advances and an increased understanding of the clinical significance of measuring these properties. This review will evaluate in-vivo biomechanical properties obtained by current technologies and compare them regarding their relevance to established biomechanical properties obtained by gold-standard ex-vivo techniques normally conducted on elastic materials.

Recent findings: Several new technologies have appeared in recent years, including vibrational optical coherence tomography (VOCT) and the corneal indentation device (CID). These techniques provide promising new opportunities for minimally invasive and accurate measurements of corneal viscoelastic properties.

Summary: Alterations in corneal biomechanics are known to occur in several corneal degenerative diseases and after refractive surgical procedures. The measurement of corneal biomechanical properties has the capability to diagnose early disease and monitor corneal disease progression. Several new technologies have emerged in recent years, allowing for more accurate and less invasive measurements of corneal biomechanical properties, most notably the elastic modulus.

综述的目的:近年来,角膜生物力学领域发展迅速,这反映了技术的进步以及对测量这些特性的临床意义的进一步了解。本综述将评估当前技术获得的体内生物力学特性,并将其与通常在弹性材料上采用的金标准体外技术获得的既定生物力学特性进行比较:近年来出现了一些新技术,包括振动光学相干断层扫描(VOCT)和角膜压入装置(CID)。这些技术为微创、精确测量角膜粘弹性特性提供了新的机遇。摘要:众所周知,角膜生物力学的改变发生在多种角膜退行性疾病和屈光手术后。角膜生物力学特性的测量能够诊断早期疾病并监测角膜疾病的进展。近年来出现了几种新技术,可对角膜生物力学特性(尤其是弹性模量)进行更精确、创伤更小的测量。
{"title":"New forays into measurement of ocular biomechanics.","authors":"Emma Hammelef, Christopher J Rapuano, Dominick A Benedetto, Zeba A Syed, Jonathan S Myers, M Reza Razeghinejad, Fred H Silver, Jose S Pulido","doi":"10.1097/ICU.0000000000001032","DOIUrl":"10.1097/ICU.0000000000001032","url":null,"abstract":"<p><strong>Purpose of review: </strong>The field of corneal biomechanics has rapidly progressed in recent years, reflecting technological advances and an increased understanding of the clinical significance of measuring these properties. This review will evaluate in-vivo biomechanical properties obtained by current technologies and compare them regarding their relevance to established biomechanical properties obtained by gold-standard ex-vivo techniques normally conducted on elastic materials.</p><p><strong>Recent findings: </strong>Several new technologies have appeared in recent years, including vibrational optical coherence tomography (VOCT) and the corneal indentation device (CID). These techniques provide promising new opportunities for minimally invasive and accurate measurements of corneal viscoelastic properties.</p><p><strong>Summary: </strong>Alterations in corneal biomechanics are known to occur in several corneal degenerative diseases and after refractive surgical procedures. The measurement of corneal biomechanical properties has the capability to diagnose early disease and monitor corneal disease progression. Several new technologies have emerged in recent years, allowing for more accurate and less invasive measurements of corneal biomechanical properties, most notably the elastic modulus.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"225-231"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1